TY - JOUR
T1 - Pancreastatin
T2 - Characterization of biological activity
AU - Zhang, Tao
AU - Mochizuki, Tohru
AU - Kogire, Masafumi
AU - Ishizuka, Jin
AU - Yanaihara, Noboru
AU - Thompson, James C.
AU - Greeley, George H.
N1 - Funding Information:
Supported by grants from the National Institutes of Health (DK 15241) and the
PY - 1990/12/31
Y1 - 1990/12/31
N2 - Pancreastatin (PST) (1-49) was first isolated from the porcine pancreas and can inhibit glucose-induced insulin release. PST (33-49), a PST C-terminal fragment, can also inhibit insulin release. The purpose of this study was to determine the shortest C-terminal biologically active fragment of PST, in terms of inhibition of insulin release from the isolated perfused rat pancreas. Porcine PST (1-49) and C-terminal fragments, PST (33-49), PST (35-49), PST (37-49) and PST (39-49) were synthesized by solid-phase methodology. PST (1-49), PST (33-49) and PST (35-49), at 10 nM, significantly (p <0.05) inhibited insulin release from isolated perfused rat pancreas: the first phase was inhibited by 15.6±2.4, 24.4±6.5 and 12.5±1.9% and the second phase, 18.9±2.7, 25.7±4.8 and 20.1±1.9% by PST (1-49), PST (33-49) and PST (35-49), respectively. PST (35-49) shows a dose-dependent inhibition of insulin release. PST (37-49) and PST (39-49) were, however, inactive. Our results indicate that the shortest C-terminal biologically active fragment is PST (35-49). These data further indicate that the C-terminal portion of PST is primarily responsible for the biological activity of PST.
AB - Pancreastatin (PST) (1-49) was first isolated from the porcine pancreas and can inhibit glucose-induced insulin release. PST (33-49), a PST C-terminal fragment, can also inhibit insulin release. The purpose of this study was to determine the shortest C-terminal biologically active fragment of PST, in terms of inhibition of insulin release from the isolated perfused rat pancreas. Porcine PST (1-49) and C-terminal fragments, PST (33-49), PST (35-49), PST (37-49) and PST (39-49) were synthesized by solid-phase methodology. PST (1-49), PST (33-49) and PST (35-49), at 10 nM, significantly (p <0.05) inhibited insulin release from isolated perfused rat pancreas: the first phase was inhibited by 15.6±2.4, 24.4±6.5 and 12.5±1.9% and the second phase, 18.9±2.7, 25.7±4.8 and 20.1±1.9% by PST (1-49), PST (33-49) and PST (35-49), respectively. PST (35-49) shows a dose-dependent inhibition of insulin release. PST (37-49) and PST (39-49) were, however, inactive. Our results indicate that the shortest C-terminal biologically active fragment is PST (35-49). These data further indicate that the C-terminal portion of PST is primarily responsible for the biological activity of PST.
UR - http://www.scopus.com/inward/record.url?scp=0025569427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025569427&partnerID=8YFLogxK
U2 - 10.1016/S0006-291X(05)80907-6
DO - 10.1016/S0006-291X(05)80907-6
M3 - Article
C2 - 2268319
AN - SCOPUS:0025569427
SN - 0006-291X
VL - 173
SP - 1157
EP - 1160
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -